Skip to main content
Shanghai Junshi Biosciences Co., Ltd. logo

Shanghai Junshi Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 1877 ISIN · CNE100003FF7 HKEX Manufacturing
Open in API
Filings indexed 1,740 across all filing types
Latest filing 2025-09-29 Declaration of Voting R…
Country HK Hong Kong
Listing HKEX 1877

About Shanghai Junshi Biosciences Co., Ltd.

http://www.junshipharma.com

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company established in 2012. It is dedicated to the discovery, development, clinical research, and commercialization of innovative therapeutics, prioritizing the creation of first-in-class and best-in-class drugs. The company utilizes a global integrated R&D system and proprietary full life cycle antibody development platform technology to build a diversified and complementary pipeline. Junshi Biosciences operates as a full-chain entity, integrating research, production, and commercialization capabilities to maintain global competitiveness in the biopharmaceutical sector.

Recent filings

Filing Released Lang Actions
POLL RESULTS OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement of the poll results from the 2025 first Extraordinary General Meeting (EGM) of Shanghai Junshi Biosciences Co., Ltd., detailing attendance, voting numbers, percentages, and the outcome of each resolution. This matches the definition of Declaration of Voting Results & Voting Rights Announcements.
2025-09-29 English
ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR CHANGE IN COMPOSITION OF THE REMUNERATION AND APPRAISAL COMMITTEE AND THE NOMINATION COMMITTEE APPOINTMENT OF EMPLOYEE REPRESENTATIVE DIRECTOR ABOLISHMEN
Board/Management Information Classification · 93% confidence The document is an announcement by Shanghai Junshi Biosciences under Hong Kong Listing Rules Rule 13.51(2) regarding the election of an independent non-executive director, changes in the composition of the Remuneration and Appraisal Committee and Nomination Committee, the appointment of an employee representative director, and the abolishment of the Board of Supervisors. This clearly pertains to Board/Management Information, i.e., changes to the board structure and committee memberships. It does not constitute an earnings release, financial report, or regulatory filing beyond board changes.
2025-09-29 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Governance Information Classification · 85% confidence The document is a formal listing of the company’s board composition, director roles, and committee memberships—it defines the board structure and governance framework rather than announcing financial results or a specific change event. This aligns with a Governance Information filing (CGR), which covers internal rules, board structure, and governance practices. It is not simply a notice of a report publication or a personnel change announcement, nor is it financial reporting. Therefore, it is classified as Governance Information (CGR).
2025-09-29 English
ARTICLES OF ASSOCIATION
Governance Information Classification · 95% confidence The document is the full text of the “Articles of Association” of Shanghai Junshi Biosciences Co., Ltd., which sets out the company’s internal rules, governance structure, shareholders’ rights, board duties, and related corporate governance provisions. This is not an announcement of a report, nor is it financial results, a regulatory notice, or a proxy statement; rather, it is the company’s charter/bylaws. Accordingly, it falls under Governance Information (CGR).
2025-09-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-09-29 English
2025 Interim Report
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled '2025 INTERIM REPORT' and contains comprehensive financial statements, including the 'Condensed Consolidated Statement of Profit or Loss', 'Condensed Consolidated Statement of Financial Position', and 'Management Discussion and Analysis' for the six months ended 30 June 2025. It meets the criteria for an Interim/Quarterly Report as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-09-26 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.